

# Inhibitor Working Party

## Membership

P Collins (Chair)  
D Hart (secretary)  
E Chalmers  
C Hay  
R Liesner  
B Palmer  
S Rangarajan  
K Talks  
M Williams

The working party reformed in March 2011

There has been one meeting held to date.

## Activities

### *Revision of UKHCDO Inhibitor guidelines*

Areas that particularly require updating are: immune tolerance in the light of the results of the international immune tolerance study, use of single high dose infusions of rFVIIa, surgery and prophylaxis. The completion of the guideline has been delayed because of emerging data especially in the field of immune tolerance which needs to be incorporated.

### *Inhibitor surveillance in previous untreated patients*

UKHCDO has undertaken a national procurement exercise assuming that if patients change from one type of factor VIII to another the risk of inhibitor formation is low. Given the available data this is a reasonable assumption but because the procurement exercise has resulted in many patients changing treatment it is important that close surveillance is undertaken at this time.

All centres have been asked to submit information on inhibitor tests taken both before and after the new contract came into effect so that the effect of switching can be followed closely. It is recommended that all patients who switch products should have an inhibitor test done both before a switch and twice in the 6 months after a switch. The incidence of new inhibitors will be identified after switching and data from patients that did not switch treatment will be used for comparison.

The data on inhibitors and switching will be combined with the revised quarterly data collected by the NHD that allows a prospective assessment of risk factors for inhibitor

development in PTPs. This data collection has been on-going for 3 years. Initial checks on the completeness of the data are being performed before initial analysis.

#### *Analysis of data held by NHD*

The working party is collaborating with the NHD to undertake two analyses:

1. Inhibitor formation in patients with severe haemophilia A dependent on concentrate of first exposure.
2. Inhibitor formation in patients with severe haemophilia A dependent on age. This work has shown that inhibitors increase in patients over the age of 60 years and has now been published.

#### *Publication*

The incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom.

Hay CR, Palmer B, Chalmers E, Liesner R, Maclean R, Rangarajan S, Williams M, Collins PW. Blood. Epub Apr 6, 2011

Dr Peter Collins  
Chairman, Inhibitor Working Party  
July 2011